Geron Profile

3.74
USD 0.14  3.89%
28%
10%

Acquisition by Fritzky Edward V of 6250 shares of Geron subject to Rule 16b-3

Geron Corporation insider trading alert for grant of common stock by Fritzky Edward V, the corporate stakeholder, on June 14, 2018. This event was filed by Geron Corp with SEC on 2008-05-29. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Geron Summary

Geron Corporation (GERN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 15 people. Geron is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 649.05 M. Geron Corporation conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 173.08 M outstanding shares of which 42.68 M shares are currently shorted by private and institutional investors with about 10.2 trading days to cover. GERON CORP currently holds about 89.78 M in cash with (20.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.52.
Check Geron Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 3.74HorizonTargetOdds Above 3.74
21.04%30 days 3.74 78.85%
Based on normal probability distribution, the odds of Geron to move above current price in 30 days from now is about 78.85% (This Geron Corporation probability density function shows the probability of Geron Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares19.7 M83.9 M
Blackrock IncCommon Shares11.8 M50.3 M
Group One Trading LpCall Options706.3 K3 M
Susquehanna International Group LlpPut Options362.6 K1.5 M
View Geron Diagnostics

Selected Geron Corporation Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Geron Against Markets

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
90 
Equity ratings for Geron Corporation are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California. Geron operates under Biotechnology classification in USA and traded on NASDAQ. It employs 15 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameGeron Corporation
President CEO, DirectorJohn ScarlettView All
Thematic Classification
Currently Active Investing Idea
  Cancer Fighters
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
LocationCALIFORNIA, U.S.A
Business Address149 Commonwealth Drive
ExchangeNASDAQ
CIK Number00886744.0
CUSIP374163103
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.geron.com
Contact Number650 473 7700
CurrencyUSD - US Dollar

Recommendations

Geron Analyst Recommendations
Target PriceAdvice# of Analysts
4.17Buy3Odds
Geron Corporation current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Geron Analyst Advice  

Directors

Geron Corporate Directors
Daniel Bradbury Independent Director
Robert Spiegel Independent Director, Ph.D
Karin Eastham Independent Director, MBA
Please also check Risk vs Return Analysis. Please also try Transaction History module to view history of all your transactions and understand their impact on performance.